Definitive Proxy Filed for BioMarin Acquisition; Shareholder Vote Set for March 3

summarizeZusammenfassung

The filing of this definitive proxy statement is a critical procedural step towards the completion of the previously announced acquisition of Amicus Therapeutics by BioMarin Pharmaceutical Inc. for $14.50 per share in cash. This document provides shareholders with comprehensive details, including the unanimous board recommendation, financial advisor opinions, and the formal date for the special meeting to vote on the transaction. The cash consideration offers immediate liquidity and a substantial premium over the company's stock price prior to the merger announcement. While a stockholder lawsuit has been filed challenging the preliminary proxy, the company asserts these claims are without merit, a common occurrence in M&A transactions. The successful completion of this merger, anticipated in Q2 2026, is contingent on shareholder approval and regulatory clearances, which are progressing.

check_boxSchlusselereignisse

• Definitive Proxy Filed

  Amicus Therapeutics filed its definitive proxy statement (DEFM14A) for the proposed acquisition by BioMarin Pharmaceutical Inc.

• Shareholder Vote Scheduled

  A special meeting of stockholders is scheduled for March 3, 2026, to vote on the merger agreement.

• Merger Consideration Details

  Shareholders are set to receive $14.50 per share in cash, representing a 33% premium over the closing price on December 18, 2025, the day prior to the merger announcement.

• Board Unanimously Recommends Merger

  The Board of Directors unanimously recommends stockholders vote 'FOR' the merger proposal, the compensation proposal, and the adjournment proposal.

auto_awesomeAnalyse

The filing of this definitive proxy statement is a critical procedural step towards the completion of the previously announced acquisition of Amicus Therapeutics by BioMarin Pharmaceutical Inc. for $14.50 per share in cash. This document provides shareholders with comprehensive details, including the unanimous board recommendation, financial advisor opinions, and the formal date for the special meeting to vote on the transaction. The cash consideration offers immediate liquidity and a substantial premium over the company's stock price prior to the merger announcement. While a stockholder lawsuit has been filed challenging the preliminary proxy, the company asserts these claims are without merit, a common occurrence in M&A transactions. The successful completion of this merger, anticipated in Q2 2026, is contingent on shareholder approval and regulatory clearances, which are progressing.